Literature DB >> 18086412

Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.

Hiroaki Mitsuya1, Kenji Maeda, Debananda Das, Arun K Ghosh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18086412     DOI： 10.1016/S1054-3589(07)56006-0

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN： 1054-3589


× No keyword cloud information.
  28 in total

1.  Transition states of native and drug-resistant HIV-1 protease are the same.

Authors:  D Randal Kipp; Jennifer S Hirschi; Aya Wakata; Harris Goldstein; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

Review 2.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

3.  Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Mol Interv       Date:  2009-04

4.  Room Temperature Neutron Crystallography of Drug Resistant HIV-1 Protease Uncovers Limitations of X-ray Structural Analysis at 100 K.

Authors:  Oksana Gerlits; David A Keen; Matthew P Blakeley; John M Louis; Irene T Weber; Andrey Kovalevsky
Journal:  J Med Chem       Date:  2017-02-28       Impact factor: 7.446

5.  Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors.

Authors:  John M Louis; Annie Aniana; Irene T Weber; Jane M Sayer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

6.  Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Ravikiran S Yedidi; Rui Zhao; Hironori Hayashi; Kazuya Hasegawa; Tomofumi Nakamura; Cuthbert D Martyr; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Luke A Kassekert; Prasanth R Nyalapatla; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

8.  Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.

Authors:  Arun K Ghosh; W Sean Fyvie; Margherita Brindisi; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem Lett       Date:  2017-09-06       Impact factor: 2.823

9.  GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

Authors:  Yasuhiro Koh; Debananda Das; Sofiya Leschenko; Hirotomo Nakata; Hiromi Ogata-Aoki; Masayuki Amano; Maki Nakayama; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.